Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,033,743 shares of the biopharmaceutical company’s stock after buying an additional 16,096 shares during the period. Wellington Management Group LLP owned approximately 0.97% of Intra-Cellular Therapies worth $86,338,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ITCI. Norges Bank purchased a new position in shares of Intra-Cellular Therapies during the fourth quarter worth approximately $268,347,000. Raymond James Financial Inc. acquired a new position in shares of Intra-Cellular Therapies during the 4th quarter worth $76,451,000. TimesSquare Capital Management LLC grew its position in Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock worth $70,179,000 after buying an additional 402,186 shares during the period. Franklin Resources Inc. grew its holdings in shares of Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock worth $129,463,000 after acquiring an additional 155,655 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Intra-Cellular Therapies by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after buying an additional 93,107 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Performance

Shares of ITCI opened at $131.87 on Friday. The business’s 50-day moving average price is $129.62 and its 200 day moving average price is $101.43. The stock has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1-year low of $64.09 and a 1-year high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. On average, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ITCI shares. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Piper Sandler reiterated a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $106.23.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.